Granulocyte colony-stimulating factor (G-CSFI is the major regulator of proliferation and differentiation of neutrophilic granulocyte precursor cells. G-CSF activates multiple signaling molecules, including the JAKl and JAK2 kinases and the STAT transcription factors. To investigate G-CSF signaling events regulated by the JAK-STAT pathway, we have generated UT7-epo cells stably expressing either wild-type ( w t l G-CSF receptor or a series of C-terminal deletion mutants. Gel mobility shift and immunoprecipitation/Western analysis showed that STAT5 is rapidly activated by G-CSF in cells expressing the wt G-CSF receptor, in addition t o the previously reported STAT3 and STATl. Mutants lacking any tyrosine residues in the cytoplasmic domain maintain their ability t o activate STAT5 and STATl but cannot activate STAT3, implying that STAT5 and STATl activation does not require receptor tyrosine phosphorylation. We also observed significant changes in the ratio of STATl:STAT3:STAT5 acti-RANULOCYTE colony-stimulating factor (G-CSF) specifically regulates the proliferation and differentiation of neutrophilic granulocyte precursor cells from bone marrow.' In addition, G-CSF plays an important role in host defense by supporting and activating mature neutrophils.' The receptor for G-CSF (G-CSFR) is a member of the type I cytokine receptor superfamily and appears to consist of a single polypeptide chain.' Dimerization of two G-CSFR chains forms a high-affinity binding site for G-CSF. G-CSFR shares a strong similarity to gp130, the P-chain of the interleukin-6 (IL-6) receptor, which is the signal-transducing component of the IL-6, oncostatin M (OSM), and leukemia inhibitory factor (LIF) receptors.' It has been shown that this group of cytokines induces tyrosine phosphorylation of distinct JAK kinases and STAT protein^.^.^ The external domains of both G-CSFR and gp130 contain an Ig-like domain, a cytokine receptor homologous ( C M ) domain, and three fibronectin type I11 repeats.' The cytoplasmic domains of gp130 and G-CSFR contain regions of sequence homology termed Boxl, Box2, and Box3, which are thought to be involved in initiation of signaling events from these receptors. Some of these sequences have been implicated in the transduction of the G-CSF growth ~i g n a l .~.~ In addition, tyrosine residues in the G-CSFR cytoplasmic domain have been implicated in triggering differentiati~n.'.~ Like the IL-6 family of cytokines, binding of G-CSF to its receptor results in rapid tyrosine phosphorylation of the receptor and consequently activation of the JAK-STAT path~ay.'.'~ Despite recent progress in unraveling G-CSF signaling events, the mechanisms by which G-CSF uses JAK-STAT signaling to accomplish its distinct spectrum of biologic activities remains largely unclear. To address this issue, we have generated an extensive collection of G-CSFR truncation mutants sequentially removing the conserved domains thought to be functionally important and have introduced them into human UT-7epo cells. We report here that G-CSF activates JAK kinases, STAT5, STAT3, and STATl through vated by various G-CSF receptor C-terminal deletion mutants. These mutant receptors were further used t o investigate the role of JAKs and STATs in G-CSF-mediated responses in these cells. We found that JAK activation correlates with G-CSF-induced cell proliferation, whereas STAT activation is not required. We have also identified three classes of G-CSF immediate early genes, whose activation correlates with the activation of distinct JAK-STAT pathways. Our data show that, whereas c-fos is regulated through a pathway independent of STAT activation, oncostatin M, IRF-1, and egr-l are regulated by an STAT5-dependent pathway and fibrinogen is regulated by an STAT3-dependent pathway. In conclusion, our results suggest that G-CSF regulates its complex biologic activities by selectively activating distinct early response genes through different JAK-STAT signaling molecules.
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cDNA as a template, truncation mutants were constructed by replacing the Eco47III-Xba I fragment, which contains all of the cytoplasmic region and part of the extracellular domain with the corresponding PCR products containing only a portion of the cytoplasmic domain. Paired with a forward primer spanning the region containing the Eco47III site, the following oligonucleotides were used as the reverse PCR primers: MGRl (A644), 5'-TGA CAC CCG ACC CAG ACC GT-3'; MGR2 (A674), 5"GAA CCA CTA ACT ACC GTG CGA CCT C-3'; MGR3 (A684), 5"GCC AAA GAA CAG AAG GAG GTC AA-3'; MGR4C (A703), 5"GGA C'M GGT CCC GAC CTT CC-3'; MGR4D (A709), 5"GAG GAA CCT CGT GTA TCC GG-3'; MGR4 (A717), 5"TGA CCA ACC TIT AAA GAG AAC CTA-3'; and MGR5 (A738). 5'-CGA CCA CCC CGA GAG TTC GTG GAC T-3'."
Cell culture and transfection. UT-7epo cellsI4 were a gift from SmithKline Beecham Pharmaceuticals (Dr Connie Erickson-Miller. King of Prussia, PA). The untransfected UT-7epo cells were maintained in Iscove's modified Dulbecco's medium (IMDM; GIBCO-BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS) and 2 UlmL erythropoietin (Epo; R&D, Minneapolis, MN). Stable cell lines were maintained in the growth medium containing 200 yglmL of hygromycin. The IL-3-dependent NFS-60 cells were a gift from Dr James Ihle (Memphis, TN)," AML-193 cells were obtained from the ATCC (Rockville, MD), and both cell lines were maintained as COS-l cell transfections were performed using the diethylaminoethyl (DEAE)-dextran method as described." UT-7epo cells were cotransfected with G-CSFR expression plasmids and the hygromycin selection marker expression plasmid pMCl hygro by CellFECTIN (GIBCO-BRL) as suggested by the manufacturer. The transfected cells were cultured for 24 hours and then selected with hygromycin-containing (200 yg/mL) medium for approximately 10 days.
Fluorescence-activated cell sorter (FACS) sorting and analysis. To select for cell populations expressing high levels of G-CSFR, the hygromycin-resistant cells were stained with phycoerythrin (PE)-conjugated G-CSF (R&D) as suggested by the manufacturer. Flow cytometry sorting was performed using a FACSstar instrument (Becton Dickinson, San Jose, CA) and the positive cells were pooled, expanded, and subjected to two additional rounds of FACS sorting.
Preparation of nuclear extracts and gel retardation assays. Nuclear extracts were prepared as de~cribed.'~ The oligonucleotides used were m67 and IRF-l,''.19 which are GAS sequences that bind to STAT proteins activated by a variety of cytokines. Gel mobility shift assays and antibody supershift experiments were performed as described.17
Preparation of cell lysates and immunoblotting. To examine phosphorylation of STAT proteins and JAK kinases, cells were deprived of cytokines overnight before treatment with G-CSF at 10 nglmL for 10 minutes. Induced or uninduced cells were lysed and immunoblotting was performed as described.'" The STAT5 antibody was from Santa Cruz Biotechnology, Inc (Santa CNZ, CA). The STAT3 antibody, raised against amino acids 688 to 727 of STAT3, and the STAT1 antibody, raised against the C-terminal 36 amino acids of p91, are gifts of Dr J.E. Damell Jr.*".*' The JAKl and JAK2 antibodies were from Pharmingen (San Diego, CA) and antiphosphotyrosine antibody 4G10 was from Upstate Biotechnology Inc (Lake Placid, NY).
Reverse transcriptase-PCR (RT-PCR).
UT-7epo stable cell lines were starved overnight without Epo in growth medium containing 0.5% FBS. The starved cells were either left untreated or treated with G-CSF (10 ng/mL) for 30 minutes or 2 hours in the presence of cycloheximide (10 yg/mL). Total RNA was prepared from 1 X IO' cells using the QIAshredder and RNeasy kit (QIAGEN Inc, Chatsworth, CA), and first-strand cDNAs were prepared using the Superscript Preamplification System (GIBCO-BRL). The RT-PCR conditions that gave the optimal signal to noise ratio for the induced genes were determined individually using RNA prepared from the MGRwt cells. PCR was performed as suggested by the manufacturer (GIBCO-BRL) for 25 cycles and the annealing temperature was 58°C for all of the primer sets. The human c-fos and GAPDH PCR primers were purchased from Clontech Laboratories, Inc (Palo Alto, CA). The OSM primers (forward primer, 5'-AAC AAC ATC TAC TGC ATG GCC-3'; and reverse primer, 5'-ACT GAG TGC ATG AAG CGA TG-3'). IRF-I primers (forward primer, 5'-TGG GCC CCT CTT ATT CCT CTA-3'; and reverse primer, 5'-TCT GGG GTC ACT GGT CTG TTC-3') and fibrinogen primers (forward primer, 5'-GGC ACT TAC TCA AAA GCA TCT ACT CC-3'; and reverse primer, 5'-TGT TTG GCT CCC CCC AGG TGG TGT TG-3') were synthesized using an Oligo l0OOM DNA Synthesizer (Beckman, Fullerton, CA). The PCR products were resolved by 2% agarose gels and visualized by ethidium bromide staining.
Proliferation assay. The proliferation assays were set up in 96-well cell culture plates at 2 X lo4 cells and 150 pL per well with or without G-CSF at the concentrations indicated. Each point was performed in quadruplicate. Cells were treated for 2 days and then 15 pL of the cell proliferation reagent WST-l (Boehringer Mannheim, Indianapolis, IN) was added to each well and incubated for 1 hour at 37°C. WST-l assay measures the overall activity of mitochrondrial dehydrogenases in the samples. Absorbance was measured at 450 nm wavelength using a Microplate Autoreader (BIO-TEK Instruments, Inc. Winooski, VT). amount of STAT1 in AML-193 cells. Using the IRF-I GAS response element in an oligonucleotide pull downWestern blot analysis, we confirmed these results: in addition, we showed that STATS is also activated strongly by G-CSF in AML-193 cells (Fig 3B) . Figure 3C shows the same experiments performed using lysates from NFS-60 cells. An identical pattern of STAT activation is observed. As a positive control for STATS activation, NFS-60 cells were also induced with IL-3. We observed activation of STATS predominantly, consistent with previous reports (Fig 3C) . Gel mobility shift and antibody supershift assays using m67 as a probe showed that the STAT1 homodimer, STATI/STAT3 heterodimer, and STAT3 homodimer are activated by G-CSF in the MGR4D (A709) stable transfectant (shown in the left panel of Fig 3D) . Because the m67 probe does not bind to STAT5 efficiently, another probe, IRF-I, was used to ana-
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lyze the same extracts. Using this probe. STATS and STATl homodimers were detected (shown in the right panel of Fig  3D) . Similar data were obtained from MGRwt cells (data not shown). although the observed level of STATl activation was lower. as discussed below. Our data show that the UT7epo stable cell lines displayed the same pattern of JAK-STAT activation as did myeloid cells expressing endogenous G-CSFR and therefore provide a useful model system for further study.
We prepared nuclear extracts from the stable transfectants expressing wt or mutant G-CSFRs after treatment with either suboptimal or saturating levels of G-CSF for various times. Two STAT-binding elements, m67 (which detects STAT3 homodimer. STAT3/STATl heterodimer. and STAT1 homodimer; Fig 4A) and IRF-l (which detects STAT5 and STAT1 homodimers; Fig 4R) . were used as probes for gel mobility shift assays. Truncation of the G-CSFR to amino acid 708 [MGR4D (A709). 4 (A717). and S (A738)I still allows efficient activation of STAT3. However, removal of 6 additional amino acids, including tyrosine 703 [MGR4C (A703)] greatly reduced STAT3 activation, but had no effect on STAT1 activation (Fig 4A) . Further truncation of the receptor to amino acid 673 [MGR 2 (A674)], which removes the Box2 homology region, reduced STAT1 activation to barely detectable levels (Fig 4A and B) . STATS activation parallels that of STATI, with the MGR3 (A684) mutant showing efficient STATS activation and MGR2 (0674) showing greatly reduced STATS activation (Fig 4B) . This finding implies that, unlike STAT3, efficient STATS and STAT1 activation does not require receptor tyrosine phosphorylation. These experiments also show that, for the mutants that allow STATS and/or STAT3 activation, we do not detect major differences in either the time course of STAT activation or shifts in the G-CSF dose-response curve relative to the wt receptor. However. we did observe significant changes in the ratio of STAT1:STATj:STATS activated by the various C-terminal deletion mutants. For example, STATl was only activated slightly in the MGRwt stable transfectant, whereas some mutants, notably MGR3 (A684), MGR4C (A703) and MGR4D (A709) showed dramatically increased levels of both STAT1 homodimer and STAT11 STAT3 heterodimer formation in response to G-CSF (Fig  4A and B) .
Analysis of STAT3 and STATS activation in the stable cells expressing mutant receptors by immunoprecipitation/ antiphosphotyrosine Western blot analysis generally confirmed the results observed in the gel mobility shift assays (Fig SA and B) . Efficient STATS activation is evident in cells expressing wt or mutant receptors MGR3 (A684)"GRS (A738), with a very low level being observed in cells expressing MGR2 (A674) (Fig SB) . A small amount of STAT3 was activated by the MGR3 (A684) mutant. as shown in Fig SA, which is consistent with the formation of a minor amount of STATl/STAT3 heterodimer in the MGR3 (A684) nuclear extract (Fig 4A) . Efficient STAT3 activation is seen in cells expressing wt or mutant receptors MGR4 (A717)-S (A738). We also tested the ability of these mutant receptors to activate JAKl and JAK2 kinases. JAKl and JAK2 are activated by MGRwt and all of the mutant receptors, with the exception of MGR1 (A644) (Fig SC and D) . MGR1 (A644) contains only 18 amino acids of the cytoplasmic domain of the receptor, up to the C-terminal boundary of the Box 1 homology region. Our data suggest that sequences downstream of Box 1 are important for G-CSF-induced JAK activation. The level of JAKl activation by the MGR2 (A674) mutant is substantially reduced, implying that Box2 also contains sequences important for JAK I activation. Both MGR3 (A684) and MGRS (A738) stable transfectants contain a minor population of cells expressing very high level of receptors (Fig 2) . This may lead to the activation of these two mutant receptors in the absence of G-CSF. resulting in the somewhat higher basal activation of JAKl and JAK2 shown in Fig SC and D. Activation qf ear!\) response genes by wt and mutant G- (Fig 6 and data not  shown) . These genes contain GAS-like response elements in their promoters that could be the binding sites for G-CSFactivated STAT complexes. We therefore examined the ability of each of the mutant receptors to induce expression of these genes. The c-fos proto-oncogene, which is involved in mitogenic response regulated by many growth factors, is efficiently activated by the wt and all of the mutant receptors except MGR1 (A644) (Fig 6A) . In contrast, two other G-CSF-regulated immediate early genes, OSM (which belongs to the IL-6 cytokine superfamily) and IRF-I (which is a transcription factor inducible by interferon-? and IL-6). are induced by all the mutants except MGR I (A644) and MGR2 (A674) (Fig 6B and C) . We observed a similar activation pattern for another G-CSF-regulated gene, egr-l (data not shown). We also analyzed the activation of fibrinogen by G-CSF treatment and observed the induction of fibrinogen mRNA in the cell lines expressing MGR4D (A709), MGR4 (A717). MGR5 (A738), and MGRwt (Fig 6D) . These are the receptor constructs that contain at least the most Nterminal tyrosine residue. Y703 (Fig I) , and are the only ones capable of activating STAT3 homodimer complex ( Fig  4A) . By cotransfecting the MGR expression plasmids in a transient transfection reporter assay in HepG2 cells, we have also observed a similar dependence on Y703 for the activation of reporters containing STAT3-selective response elements (data not shown). We have, therefore, identified three classes of immediate early genes regulated by G-CSF that require different regions of the receptor cytoplasmic domain for efficient induction.
CSFRs. G-CSF induces transcriptional activation of a spe-
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Induction of proliferation by wt and mutant G-CSFRs.
G-CSF induces short-term proliferation of the MGRwt UT7epo cells as assessed by either a WST-I proliferation assay or direct cell counting (Fig 7 and data not shown) . To examine whether JAK and STAT activation contributes to this G-CSF-induced proliferative signal, we examined all of the G-CSF receptor-transfected UT-7epo stable cell lines for G-CSF-induced proliferation using the WST-I assay (Fig 7) . G-CSF-induced proliferation of most of the MGR mutant cell lines, including MGR2 (A674). which activates both JAKl and JAK2, cannot activate STAT3 and is only capable of marginally inducing STAT5 (Figs 4 and 5) . The only cell line that failed to proliferate in response to G-CSF was the stable cell pool expressing the MGR1 (A644) mutant. MGR1 (A644) lacks receptor sequences C-terminal of Box1 and does not detectably activate JAK or STAT proteins. To determine if any of the MGR mutants show altered sensitivities to G-CSF, we have performed dose-response and time course analyses of MGRwt and all of the MGR mutant stable cell lines by the WST-I proliferation assay and cell counting. We did not observe any consistent differences in sensitivity to G-CSF between the wt and mutant receptors (data not shown).
For For personal use only. on September 24, 2017. by guest www.bloodjournal.org From been shown to be required for JAK activation.''-*' However, JAK activation alone is not sufficient for effective STAT activation in response to G-CSF. STAT5 activation requires additional receptor sequences that include the Box2 homology region. Our data show that STAT5 can be activated by mutant receptors that lack tyrosine residues, indicating that G-CSFR phosphorylation is not required for STAT5 activation. This is different from the Epo receptor system, in which Epo receptor tyrosine phosphorylation is involved in Epoinduced STAT5 activation? This finding suggests that activation of a STAT family member can proceed through different mechanisms in the context of different cytokine receptor chains. In contrast, efficient STAT3 activation requires additional receptor sequences that include at least one tyrosine, tyr 703. This is consistent with previous analyses performed using different G-CSFR mutants that also indicated that receptor tyrosines are required for STAT3 activation.*' We also observed dramatic increases in the level of STATl activation among some of the mutant receptors relative to the wt receptor, which can only activate a low level of STATl. The most noticeable increase is in mutants MGR3 (A684), MGR4C (A703), and MGR4D (A709). We have not yet detected any changes in G-CSF-triggered responses due to the higher level of STATl activation in these mutants. Further study of these mutants may provide us with insight into the role that STATl plays in G-CSF signaling.
STAT5 is known to be the major STAT activated by a variety of cytokines, including IL-2, IL-3, IL-5, granulocytemacrophage colony-stimulating factor (GM-CSF), thrombopoietin (TPO), and E~o .~' "~ In the context of Epo and IL-3 signaling, it has been suggested that STAT5 activation is involved in cell proliferation.26.'3 However, conflicting reports by other investigators indicate that STAT5 activation is not required for Epo-or IL-2-induced proliferation.2', '4 In our experiments, the MGR2 (A674) mutant, which can induce STAT5 activation only marginally, retains an ability to stimulate cell proliferation that is indistinguishable from that triggered by the wt receptor. This result suggests that, if STAT5 is required for the G-CSF proliferative signal, a very low level of STAT5 activation is sufficient for transducing that signal. We have also observed that, in NFS-60 cells, the concentration of G-CSF sufficient to give an optimal proliferative signal is much lower than that required for maximal STAT5 activation (Tian et al, unpublished results). However, we are currently unable to distinguish between a model in which very low levels of STAT5 activation are sufficient for transducing a G-CSF proliferative signal and one in which STAT5 activation is not required at all. Our data, together with previous data using less extensive sets of receptor mutants,35 clearly show that STAT3 activation is not required for a proliferative response to G-CSF, whereas JAK activation is required.
Many of the biologic effects of cytokines are thought to be the long-term consequences of the activation of distinct sets of early response genes. We examined induction of several early response genes that are regulated by G-CSF in the UT-7 cell transfectants. We were able to correlate activation of different STAT proteins with the activation of different early response genes and found that the genes fell into three distinct classes. The first class, represented by the c-fos gene, does not require STAT activation for G-CSF induction. The c-fos promoter has many regulatory elements, including a GAS response element, the serum-inducible element (SIE), that has been well characteri~ed.~~~" Our data suggest that the SIE does not play an important role in c-fos induction under these conditions. It remains to be determined which of the other c-fos response elements are important for G-CSF-induced c-fos activation. The second class of early response genes, which consists of OSM, IRF-1 and egr-1, appears to be regulated by G-CSF through the same pathway, because the activation of all three genes correlates well with STAT5 activation. STAT5 activation has recently been suggested to be involved in the transcriptional regulation of OSM by Epo and IL-3.'' We therefore conclude that G-CSF-induced STAT5 activation is likely to be involved directly in the transcriptional regulation of OSM, IRF-1, and egr-1. Both OSM and IRF-1 genes contain palindromic GAS-like response elements in their promoters (OSM, 5'-TTCCCAGAA-3'; and IRF-l, 5'-TTCCCCGAA-3') that might be the direct binding sites of the G-CSF-activated STAT5 complex. We have not been able to identify any GAS-like response element in the promoter of the published mouse egr-l gene sequence. One explanation is that a somewhat divergent response element in the egr-l promoter may be involved in STAT5 regulation. IRF-I is known to be regulated by interferon y , which predominantly activates STATl .jY Although G-CSF-induced STATl activation always correlates with STAT5 activation, the level of STATl activation is very low in the MGRwt transfectant (Fig 4) relative to the level of STAT5. Thus, STATl is unlikely to be a significant player in the transcriptional regulation of OSM, IRF-1, and egr-l by G-CSF. OSM belongs to the IL-6 cytokine superfamily, and IRF-1 and egr-1 are transcription factors that are known to have many Taken together, our data suggest that, through activation of diverse targets possessing multiple functions, STAT5 might play a critical role in G-CSF-regulated biologic activities. The third class of induced gene is represented by the fibrinogen gene. Activation of this gene correlates with the ability of mutant receptors to activate STAT3. Fibrinogen contains an imperfect palindromic GAS response element (5"GTACTG-GAA-3') in its promoter, and it was suggested previously that this response element plays a role in IL-6-regulated fibrinogen ind~ction.~' This is consistent with our observation that fibrinogen induction correlates with STAT3 activation in all of the G-CSFR constructs, because STAT3 is the major STAT activated by IL-6. Recent studies have indicated that different STAT proteins, activated by different cytokines and growth factors, bind to distinct but related GAS response elements." The specificity of STAT binding can be strongly influenced by the spacing of palindromic half sites and by the nature of sequences both flanking and between the half site seq u e n c e~.~~,~~ This in turn suggests that each member of the STAT family may activate distinct (although possibly overlapping) genetic programs through its ability to differentially interact with sequences present in promoters. Using mutants of the G-CSFR that separate the ability of G-CSF to activate STAT3 and STATS, we have provided evidence showing how this model might work. Activation of just STAT5 allows activation of only a subset of the genes normally activated by G-CSF and the additional activation of STAT3 induces another subset of G-CSF-responsive genes. Activation of these additional genes may contribute to the differences in biologic responses between G-CSF and other cytokines such as IL-3, for example, which activates predominantly STAT5 In addition, we have identified another G-CSF-triggered pathway responsible for c-fos activation that appears to be independent of STAT activation. A similar STAT-independent activation pathway has been documented for the induction of c-myc in response to E~o .~~ These different pathways leading to G-CSF induction of immediate early gene expression are shown in Fig 8. It appears that cytokines achieve specificity in part by activating distinct STAT complexes, the relative ratios of which are dependent on the sequences present in the cytokine receptor cytoplasmic domain. This then leads to induction of a specific spectrum of immediate early genes and ultimately to the execution of distinct biologic functions.
